Spertini O, Kansas G S, Reimann K A, Mackay C R, Tedder T F
Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA.
J Immunol. 1991 Aug 1;147(3):942-9.
The leukocyte adhesion molecule-1 (LAM-1, TQ=1, Leu-8) in humans, like its murine homologue, MEL-14, is the principal receptor that mediates the binding of leukocytes to high endothelial venules (HEV) of peripheral lymph nodes. In this study, several regions of the protein which mediate receptor function were identified by using a large panel of murine mAb reactive with LAM-1. Individual mAb reacted with LAM-1+ cells with characteristic intensities of immunofluorescence staining, and each bound both lymphocytes and neutrophils. Lymphocyte attachment to HEV was significantly inhibited by the binding of five mAb. In contrast, only two of these mAb were able to completely block the binding of phosphomannan monoester core complex from the yeast Hansenula holstii cell wall (PPME), a phosphomannan monoester core polysaccharide that serves as a soluble model of the natural ligand of LAM-1. Interestingly, the binding of two anti-LAM-1 mAb to cells induced a significant increase in PPME binding, reminiscent of the increase in receptor affinity observed after leukocyte activation. Antibody cross-blocking studies indicated that many of the functionally important epitopes were spatially distinct, and domain mapping indicated that they recognized distinct domains of LAM-1. The expression and function of these epitopes were further assessed by using a variety of animal species to further characterize the functionally relevant epitopes defined in these studies. At least some anti-LAM-1 mAb reacted with leukocytes from monkey, cow, rabbit, sheep, dog, cat, pig, and goat, but not from chicken, rat, or mouse. The reactivity of anti-LAM-1 mAb in several animal species correlated with the ability of leukocytes to bind PPME, and mAb that inhibited lymphocyte binding to HEV in man could also inhibit this function in rhesus monkey and dog. Thus, several LAM-1 epitopes are structurally and functionally well conserved throughout recent mammalian evolution, emphasizing an important role for LAM-1 in the regulation of leukocyte traffic.
人类白细胞黏附分子-1(LAM-1,TQ=1,Leu-8)与其鼠类同源物MEL-14一样,是介导白细胞与外周淋巴结高内皮微静脉(HEV)结合的主要受体。在本研究中,通过使用大量与LAM-1反应的鼠单克隆抗体,确定了该蛋白中几个介导受体功能的区域。单个单克隆抗体与LAM-1+细胞反应,呈现出特征性的免疫荧光染色强度,并且都能结合淋巴细胞和中性粒细胞。五种单克隆抗体的结合显著抑制了淋巴细胞与HEV的黏附。相比之下,这些单克隆抗体中只有两种能够完全阻断来自酵母霍氏假丝酵母细胞壁的磷酸甘露聚糖单酯核心复合物(PPME)的结合,PPME是一种磷酸甘露聚糖单酯核心多糖,可作为LAM-1天然配体的可溶性模型。有趣的是,两种抗LAM-1单克隆抗体与细胞的结合导致PPME结合显著增加,这让人联想到白细胞激活后观察到的受体亲和力增加。抗体交叉阻断研究表明,许多功能重要的表位在空间上是不同的,结构域图谱显示它们识别LAM-1的不同结构域。通过使用多种动物物种进一步评估这些表位的表达和功能,以进一步表征这些研究中定义的功能相关表位。至少一些抗LAM-1单克隆抗体与来自猴、牛、兔、羊、狗、猫、猪和山羊的白细胞反应,但不与来自鸡、大鼠或小鼠的白细胞反应。抗LAM-1单克隆抗体在几种动物物种中的反应性与白细胞结合PPME的能力相关,并且在人类中抑制淋巴细胞与HEV结合的单克隆抗体在恒河猴和狗中也能抑制这种功能。因此,在近代哺乳动物进化过程中,几个LAM-1表位在结构和功能上都得到了很好的保守,这强调了LAM-1在调节白细胞运输中的重要作用。